Public Consultation on the Post-market review of the use of biologics in the treatment of severe chronic plaque psoriasis
Page last updated: 5 February 2018
Accessibility
The documents on this page may not be accessible. If you need assistance please email the Review’s Secretariat.
Draft report to the Pharmaceutical Benefits Advisory Committee (PBAC) for the Post-market review of the use of biologics in the treatment of severe chronic plaque psoriasis
Public Consultation: 18 January 2018 to 02 February 2018
The Call for Submissions on the draft Report for the Post-market review of biologics in the treatment of severe chronic plaque psoriasis closed on 02 February 2018. The Department appreciates the contribution of all organisations and individuals who made a submission.
Draft Report
The draft Report is provided in six parts, in DOCX and PDF format:
Public Submissions addressing the Terms of Reference
The public submission process on the Post-market review of the use of biologics in the treatment of severe chronic plaque psoriasis closed on 15 February 2017. The Department appreciates the contribution of all organisations and individuals who made a submission.
Public Submissions on the Draft Terms of Reference
The call for submissions addressing the draft Terms of Reference (ToR) for the on the Post‑market review of the use of biologics in the treatment of severe chronic plaque psoriasis closed on16 May 2016. The Department appreciates the contribution of all organisations and individuals who made a submission.
Privacy
Unless otherwise requested, all submissions to the Review will be published on this page.
The Department of Health will not publish submissions, or parts of submissions, which contain personal information, offensive language, potentially defamatory material or copyright infringing material.
Responsibility for copyright in submissions resides with the author(s), not with the Department of Health.
All submissions will be converted to Portable Document Format (PDF) for publication and may have a different appearance to the document that was submitted.
Your submission and contact details will be stored in accordance with the Privacy Act 1988 and the Archives Act 1983. Should you have any concerns about the storage of your submission, or if you wish to gain access to make a correction, please contact the Review’s Secretariat. A copy of the Department’s privacy policy is available on request. If you wish to make a complaint about the handling of your private information, you may contact the Department of Health Privacy Contact Officer and, if unsatisfied with the response, you may submit a complaint to the Office of the Australian Information Commissioner.
Disclaimer
- The views expressed in submissions published on this website are solely those of the contributing authors or organisations.
- The Commonwealth accepts no responsibility for the completeness or accuracy of any information contained in the submissions.
- The Commonwealth makes no representations about the suitability of the information for any particular purpose. Users of the information must make their own inquiries and assessments about those matters or seek independent advice.
- Submissions are published on the understanding that the contributing authors or organisations have copyright in the submissions either by way of ownership or a licence. They retain their copyright, and by making submissions they licence the Commonwealth to publish the submissions, unless a party when making a submission has requested that it be kept confidential and the Commonwealth clearly agrees that the submission will be kept confidential.
Table of submissions addressing the draft Terms of Reference
|
Submission |
Author Name |
Document Link |
Date received |
|---|---|---|---|
|
1 |
Janssen-Cilag Pty Ltd |
16/05/2016 |
|
|
2 |
Australasian College of Dermatologists |
16/05/2016 |
|
|
3 |
AbbVie Pty Ltd |
16/05/2016 |
Table of submissions addressing the Review
|
Submission |
Author Name |
Document Link |
Date received |
Date Updated |
|---|---|---|---|---|
|
1 |
Individual |
6 February 2017 |
- |
|
|
2 |
Janssen-Cilag Pty Ltd |
Not for publication |
14 February 2017 |
5 May 2017 |
|
3 |
Eli Lilly Pty Ltd |
Not for publication |
15 February 2017 |
9 May 2017 |
|
4 |
Abbvie Pty Ltd |
Not for publication |
15 February 2017 |
- |
|
5 |
Pfizer Australia |
15 February 2017 |
1 May 2017 |
|
|
6 |
The Australasian College of Dermatologists |
27 February 2017 |
- |
